Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
- Written by: ACN Newswire - Press Releases

Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,...

Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,...

New owners Gabby and Hezi Leibovich bring back Australia’s leading ecommerce sales event with Australia Post as Major Sponsor Click Frenzy is ...

Most Australian SMEs I speak with are already having a go at AI. Some are running formal pilots, others have a team member quietly experimenting o...

AI-enabled augmented reality (AR) smart glasses are emerging as a new practical solution to fill a shortage of field service technicians maintaini...

When a midsize company expands across borders, its payroll operation becomes exponentially more complex. These organisations typically face a new ...

For years, one of the biggest digital marketing questions for businesses was ‘how do we get onto page one of Google?’ That question still matters, ...

Fleet management today is constrained by fragmented systems and heavy administrative demands. A lot of the work still relies on booking vehicles and...